Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Samuelsson

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Current Opinion in Lipidology|June 11, 2009
Dyslipidemia of kidney diseasePer-Ola Attman, Ola Samuelsson
Lakartidningen|June 14, 2019
[Severe COPD can benefit from endobronchial valves]Gerdt Riise, Therese Svanberg, Ola Samuelsson
Lancet (London, England)|November 9, 2004
Atenolol in hypertension: is it a wise choice?Bo Carlberg, Ola Samuelsson, Lars Hjalmar Lindholm
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 12, 2011
The effect of decreasing renal function on lipoprotein profilesPer-Ola Attman, Ola Samuelsson, Petar Alaupovic
Lancet (London, England)|November 1, 2005
Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysisLars Hjalmar Lindholm, Bo Carlberg, Ola Samuelsson
British Journal of Clinical Pharmacology|February 26, 2008
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversionBengt Hamrén, Hans Ericsson, Ola Samuelsson, et al.
Clinical Drug Investigation|May 31, 2007
Candesartan cilexetil in haemodialysis patientsPia Ottosson, Per-Ola Attman, Ann-Charlotte Agren, et al.
Hypertension (Dallas, Tex. : 1979)|July 14, 2004
Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertensionThórdís Hrafnkelsdóttir, Pia Ottosson, Thorarinn Gudnason, et al.
Critical Care Medicine|June 10, 2004
Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trialKristina Swärd, Felix Valsson, Per Odencrants, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 20, 2004
In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharoseLennart Rydberg, Anders Bengtsson, Ola Samuelsson, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Current Opinion in Lipidology|June 11, 2009
Dyslipidemia of kidney diseasePer-Ola Attman, Ola Samuelsson
Lakartidningen|June 14, 2019
[Severe COPD can benefit from endobronchial valves]Gerdt Riise, Therese Svanberg, Ola Samuelsson
Lancet (London, England)|November 9, 2004
Atenolol in hypertension: is it a wise choice?Bo Carlberg, Ola Samuelsson, Lars Hjalmar Lindholm
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 12, 2011
The effect of decreasing renal function on lipoprotein profilesPer-Ola Attman, Ola Samuelsson, Petar Alaupovic
Lancet (London, England)|November 1, 2005
Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysisLars Hjalmar Lindholm, Bo Carlberg, Ola Samuelsson
British Journal of Clinical Pharmacology|February 26, 2008
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversionBengt Hamrén, Hans Ericsson, Ola Samuelsson, et al.
Clinical Drug Investigation|May 31, 2007
Candesartan cilexetil in haemodialysis patientsPia Ottosson, Per-Ola Attman, Ann-Charlotte Agren, et al.
Hypertension (Dallas, Tex. : 1979)|July 14, 2004
Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertensionThórdís Hrafnkelsdóttir, Pia Ottosson, Thorarinn Gudnason, et al.
Critical Care Medicine|June 10, 2004
Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trialKristina Swärd, Felix Valsson, Per Odencrants, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 20, 2004
In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharoseLennart Rydberg, Anders Bengtsson, Ola Samuelsson, et al.
Pageof 4